Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Eisert

Showing results (471-480 of 483) with videos related to

Pageof 49
Sort By:
Nature Communications|March 15, 2026
TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathologyLaura E König, Steve Rodriguez, Clemens Hug, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Nature Cardiovascular Research|November 25, 2022
Rad regulation of Ca<sub>V</sub>1.2 channels controls cardiac fight-or-flight responseArianne Papa, Sergey I Zakharov, Alexander N Katchman, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Cell Chemical Biology|November 29, 2024
An engineered cereblon optimized for high-throughput screening and molecular glue discoveryHenry J Bailey, Jonathan Eisert, Rubina Kazi, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
Blood|July 20, 2006
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patientsKatrin Tefs, Maria Gueorguieva, Jürgen Klammt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Pageof 49

Showing results (471-480 of 483) with videos related to

Sort By:
Pageof 49
Nature Communications|March 15, 2026
TYK2 mediates neuroinflammation in Alzheimer's disease brains with TDP-43 pathologyLaura E König, Steve Rodriguez, Clemens Hug, et al.
European Journal of Cancer (Oxford, England : 1990)|December 15, 2022
Resistance to MET inhibition in MET-dependent NSCLC and therapeutic activity after switching from type I to type II MET inhibitorsRichard Riedel, Jana Fassunke, Hannah L Tumbrink, et al.
Nature Cardiovascular Research|November 25, 2022
Rad regulation of Ca<sub>V</sub>1.2 channels controls cardiac fight-or-flight responseArianne Papa, Sergey I Zakharov, Alexander N Katchman, et al.
Clinical Lung Cancer|August 17, 2024
Multicenter Real-World Analysis of Combined MET and EGFR Inhibition in Patients With Non-Small Cell Lung Cancer and Acquired MET Amplification or Polysomy After EGFR InhibitionFabian Acker, Alexandra Klein, Anna Rasokat, et al.
Cell Chemical Biology|November 29, 2024
An engineered cereblon optimized for high-throughput screening and molecular glue discoveryHenry J Bailey, Jonathan Eisert, Rubina Kazi, et al.
Clinical Lung Cancer|March 27, 2025
Tepotinib Plus an EGFR Tyrosine Kinase Inhibitor in Patients With EGFR-Mutant MET-Altered NSCLC: A Case SeriesXiuning Le, Anna Eisert, Te-Chun Hsia, et al.
Blood|July 20, 2006
Molecular and clinical spectrum of type I plasminogen deficiency: A series of 50 patientsKatrin Tefs, Maria Gueorguieva, Jürgen Klammt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|December 14, 2020
Genetic Heterogeneity of MET-Aberrant NSCLC and Its Impact on the Outcome of ImmunotherapyAnna Kron, Matthias Scheffler, Carina Heydt, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 4, 2019
K-ras Mutation Subtypes in NSCLC and Associated Co-occuring Mutations in Other Oncogenic PathwaysMatthias Scheffler, Michaela A Ihle, Rebecca Hein, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 16, 2023
RET-MAP: An International Multicenter Study on Clinicobiologic Features and Treatment Response in Patients With Lung Cancer Harboring a RET FusionMihaela Aldea, Arianna Marinello, Michael Duruisseaux, et al.
Pageof 49